The Association for Frontotemporal Degeneration

You don't have to take
this journey alone.

AFTD offers reliable information, resources,
and support for families facing FTD.

Find Support Managing FTD Newly Diagnosed

FTD is caused by
degeneration of the frontal
and/or temporal lobes of the brain.

It's the most common form of dementia for people under 60.

What is FTD?

Learn More

Diagnostic Information

Bruce Willis & FTD:
What You Need to Know

Bruce Willis’s family has announced
that he has been diagnosed with FTD.

Willis Family
Statement

AFTD
Statement

FTD Info &
Resources

Take
Action

Tuesday, November 19, 2024 | 1-2 p.m. ET

Navigating the Holidays with an FTD Diagnosis

Care Partner webinar

Care Partner Learning Series:

December 12, 2024
10:00 – 11:00 a.m. ET

Perspectives in Research Webinar

FTD Research 2024:

Where We’ve Come From and Where We’re Headed

Support groups
provide a resource,
an outlet, and a place
to connect with others
who understand.

Find Support Near You

Learn More

Newly diagnosed? Concerned about potential symptoms? Get the information you need.

Find Help

Resources for Diagnosis Support Groups

Email our HelpLine

News & Events

Advancing Hope: AFTD Staff Attend NORD Breakthrough Summit in Washington, DC

Shana Dodge, PhD, AFTD’s Director of Research Engagement and Meghan Buzby, MBA, AFTD’s Director of Advocacy and Volunteer Engagement attended the National Organization for Rare Disorders (NORD) Breakthrough Summit, held…

GemVax & KAEL Announces Results from Phase 2a Clinical Trial for PSP

South Korean biopharmaceutical company GemVax & Kael announced in late October the results from its phase 2a clinical trial evaluating a drug for PSP. While the drug failed to show…

Dear HelpLine: Navigating Travel During the Holidays

Dear HelpLine, I am thinking of traveling to see family this year for the holidays, but this would be the first time taking my wife since she was diagnosed with…

A Conversation with Alector’s Vice President of Clinical Development

Earlier this year, the biopharmaceutical company Alector announced that the U.S. Food and Drug Administration (FDA) had granted a “breakthrough therapy designation” to latozinemab, the company’s investigational drug designed to…

Vesper Bio Announces Successful Completion of Phase 1 Study for Potentially Disease-Modifying Treatment for FTD-GRN

Biotechnology company Vesper Bio announced in early September that the phase 1 clinical trial for its potentially disease-modifying treatment for FTD-GRN has successfully concluded. The company noted data from the…

AFTD Webinar: Diagnosing Primary Progressive Aphasia

With primary progressive aphasia (PPA), problems with language and communication typically deteriorate gradually over time. Initial symptoms are sometimes attributed to anxiety or stress until the ongoing symptoms become disruptive…

Reauthorize Funding for the Older Americans Act Decorative element

Tell Your Legislators: Reauthorize Funding for the Older Americans Act

You may think that because frontotemporal degeneration strikes many people in the middle of their life, that the Older Americans Act may not apply to you. But the OAA provides…

Text: AFTD Hosts 2024 Research Rountable Meeting Background: AFTD Staff and Board Members at the FTD Research Roundtable meeting.

Advancing Hope: AFTD hosts 2024 FTD Research Roundtable Meeting

The FTD Research Roundtable is an annual program designed to accelerate FTD drug development by convening various scientific stakeholders to identify common challenges and advance solutions for FTD clinical trials.…

SEE CALENDAR VIEW

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

News & Events

Have Questions?